Browsing by Author "Giwa A., Giwa H. B. F., Jamiu M. O."

Now showing 1 - 1 of 1
  • Item
    Cost of Illness Analysis of Human Immuno Deficiency Virus/Acquired Immuno Deficiency Syndrome (HIV/AIDS) in a Developing Economy.
    (Published by West African Postgraduate College of Pharmacy, 2018) Giwa A., Giwa H. B. F., Jamiu M. O.
    ABSTRACT Background: Highly Active Antiretroviral Therapy is for lifetime of the patients from time of diagnosis of HIV/AIDS. This translates into a substantial cost in drug therapy to the patients, government and donor agencies. Objective: To conduct cost of illness analysis of HIV/AIDS in a Developing Economy in 2016. Methods:A one-year retrospective review of 2560 prescriptions of 396 HIV/AIDS patients' case notes from January to December, 2016 obtained by systematic random sampling from 4800 case-notes of subjects that participated in this study was conducted. Sampling Interval =10 A data collection form was designed and used to collect data generated from the selected case notes. Cost of Illness was determined by prevalence rate method, using direct costs only. Results: The annual cost of illness for the 396 HIV/AIDS patients on highly active antiretroviral therapy was ?40,674,760 (US$127,108.3) with drug, diagnostic/monitoring tests, transport, care/support and personnel cost components of ?25,479,760; US$79,624.3 (62.64%), ?7,200,000; US$22,500 (17.71%), ?1,440,000; US$4,500(3.54%), ?2,880,000; US$9,000 (7.08%) and ?3,675,000; US$11484 (9.03%) respectively. The annual average cost of illness of HIV/AIDS was ?102,714.04 (US$320.98) ABSTRACT Background: Highly Active Antiretroviral Therapy is for lifetime of the patients from time of diagnosis of HIV/AIDS. This translates into a substantial cost in drug therapy to the patients, government and donor agencies. Objective: To conduct cost of illness analysis of HIV/AIDS in a Developing Economy in 2016. Methods:A one-year retrospective review of 2560 prescriptions of 396 HIV/AIDS patients' case notes from January to December, 2016 obtained by systematic random sampling from 4800 case-notes of subjects that participated in this study was conducted. Sampling Interval =10 A data collection form was designed and used to collect data generated from the selected case notes. Cost of Illness was determined by prevalence rate method, using direct costs only. Results: The annual cost of illness for the 396 HIV/AIDS patients on highly active antiretroviral therapy was ?40,674,760 (US$127,108.3) with drug, diagnostic/monitoring tests, transport, care/support and personnel cost components of ?25,479,760; US$79,624.3 (62.64%), ?7,200,000; US$22,500 (17.71%), ?1,440,000; US$4,500(3.54%), ?2,880,000; US$9,000 (7.08%) and ?3,675,000; US$11484 (9.03%) respectively. The annual average cost of illness of HIV/AIDS was ?102,714.04 (US$320.98)